2339-57-3

Basic information

• Product Name: o-Toluenesulfonamide, 5-fluoro- (6CI,8CI)
• Synonyms: o-Toluenesulfonamide, 5-fluoro- (6CI,8CI)
• CAS NO: 2339-57-3
• Molecular Formula: C₇H₈FNO₂S
• Molecular Weight: 189.2073232
• Product Categories: SULFONAMIDE
• Mol File: 2339-57-3.mol

Chemical Properties

• Boiling Point: 334.1 °C at 760 mmHg
• Flash Point: 155.9 °C
• Appearance: /
• Density: 1.362 g/cm³
• Vapor Pressure: 0.00013mmHg at 25°C
• Refractive Index: 1.545
• PKA: 9.96±0.60(Predicted)
• CAS DataBase Reference: o-Toluenesulfonamide, 5-fluoro- (6CI,8CI)(CAS DataBase Reference)
• NIST Chemistry Reference: o-Toluenesulfonamide, 5-fluoro- (6CI,8CI)(2339-57-3)
• EPA Substance Registry System: o-Toluenesulfonamide, 5-fluoro- (6CI,8CI)(2339-57-3)

Safety Data

• Hazardous Substances Data: 2339-57-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
o-Toluenesulfonamide, 5-fluoro(6CI,8CI) is utilized as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure and reactivity make it a valuable component in the development of new drugs with improved efficacy and selectivity.
Used in Agrochemical Industry:
In the agrochemical sector, o-Toluenesulfonamide, 5-fluoro(6CI,8CI) is employed as a precursor for the production of agrochemicals. Its potential antifungal and antibacterial properties are leveraged to create compounds that can protect crops from diseases and pests, thereby enhancing agricultural productivity.
Used in Medicinal Chemistry Research:
o-Toluenesulfonamide, 5-fluoro(6CI,8CI) serves as a versatile building block in medicinal chemistry research. Its incorporation into various molecular frameworks allows for the exploration of new chemical space and the discovery of novel biologically active compounds with potential therapeutic applications.
Used in Drug Development:
o-Toluenesulfonamide, 5-fluoro(6CI,8CI) is used in drug development as a starting material for the synthesis of new pharmaceutical agents. Its unique properties and reactivity enable the creation of diverse drug candidates that can address unmet medical needs and offer innovative treatment options for various diseases and conditions.

InChI:InChI=1/C7H8FNO2S/c1-5-2-3-6(8)4-7(5)12(9,10)11/h2-4H,1H3,(H2,9,10,11)

Upstream product

• 352-32-9 p-fluorotoluene 
• 445-05-6 5-fluoro-2-methylbenzenesulfonyl chloride 

Downstream Products

• 384-45-2 6-fluoro-1,2-benzisothiazol-3(2H)-one-1,1-dioxide 
• 1254305-50-4 C₁₆H₁₀ClF₄N₃O₃S 

Relevant articles and documents

Discovery of cyclic sulfonamide derivatives as potent inhibitors of SARS-CoV-2

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) continues to spread worldwide, with 25 million confirmed cases and 800 thousand deaths. Effective treatments to target SARS-CoV-2 are urgently needed. In the present study, we have identified a

DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS

The object of the present invention is benzothiazine derivatives having the capability of inhibiting 11β-HSD1 not only at an enzymatic level but also at a cell level. The compounds of the present invention are of general formula (I). Wherein notably R1 represents a hydrogen or OR1 represents an ester or an ether. R2 represents a naphthyl or a 1, 2, 3, 4-tetrahydro-naphthalene or a biphenyl or phenyl pyridine or a substituted phenyl. R3 represents a methyl or ethyl; R4 and R'4 represent a hydrogen.

Substituted N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl} benzamide analogs as potent Kv1.3 ion channel blockers. Part 2

We report the synthesis and in vitro activity of a series of novel substituted N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl} benzamide analogs. These analogs showed potent inhibitory activity against Kv1.3. Several demonstrated similar po

HIV INTEGRASE INHIBITORS

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

HIV integrase inhibitors

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS

The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

Bicyclic heterocycles as HIV integrase inhibitors

The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.